THOMSON MEDICAL GROUP LIMITED
(Incorporated in the Republic of Singapore)
(Company Registration No. 199908381D)

S$120,000,000 5.50% NOTES DUE 2028 TO BE ISSUED PURSUANT TO THE S$1,000,000,000 MULTICURRENCY DEBT ISSUANCE PROGRAMME OF THOMSON MEDICAL GROUP LIMITED

The Board of Directors of Thomson Medical Group Limited (the "**Issuer**") wishes to announce that it has launched and priced S$120,000,000 in aggregate principal amount of 5.50% notes due 2028 (the "**Series 003 Notes**"). The Series 003 Notes will be issued by the Issuer, as issuer, pursuant to the S$1,000,000,000 Multicurrency Debt Issuance Programme established by the Issuer on 28 June 2019 and updated on 21 April 2023 (the "**Programme**"). DBS Bank Ltd. has been appointed as the sole global coordinator and DBS Bank Ltd., Maybank Securities Pte. Ltd., Standard Chartered Bank (Singapore) Limited and United Overseas Bank Limited have been appointed as the joint lead managers and joint bookrunners in relation to the Series 003 Notes.

The principal terms of the Series 003 Notes are as follows:

Issue Size:	**S$120,000,000**
Issue Price:	**100.00% of the principal amount of the Series 003 Notes**
Denomination:	**S$250,000**
Issuer's Call Option:	**The Issuer may, by giving not less than 15 nor more than 30 days' notice to the Noteholders (which notice shall be irrevocable), redeem all (but not some only) of the Series 003 Notes on 31 May 2024 (being the date which falls 12 months from the date of issue) at the redemption amount equal to 102.75 per cent. of the principal amount of the Series 003 Notes, together with interest accrued (if any) to (but excluding) the date fixed for redemption.**
Issuer's Redemption Option for Taxation Reasons:	**At par**
Issuer's Redemption Option in the case of Minimum Outstanding Amount:	**At par**
Noteholders' Redemption Option upon cessation or suspension of trading of shares:	**At par**
Interest:	**5.50% per annum payable semi-annually in arrear**
Maturity Date:	**5 years from the date of issue**
Security:	**None**

The Series 003 Notes are expected to be issued on 31 May 2023 (subject to satisfaction of customary closing conditions) and listed on the Singapore Exchange Securities Trading Limited ("SGX-ST") on the market day after such issue.

The Series 003 Notes will constitute direct, unconditional and unsubordinated obligations of the Issuer and shall at all times rank *pari passu*, without any preference or priority among themselves, and at least *pari passu* with all other present and future unsecured obligations (other than subordinated obligations and priorities created by law) of the Issuer.

The Series 003 Notes are offered by the Issuer in Singapore pursuant to the exemptions invoked under Sections 274 and/or 275 of the Securities and Futures Act 2001 of Singapore.

The net proceeds arising from the issue of the Series 003 Notes under the Programme (after deducting issue expenses) will be used for general corporate purposes of the Group, including refinancing of borrowings, financing potential acquisitions, strategic expansions, general working capital, capital expenditure and other investments of the Group.

Application will be made to the SGX-ST for the listing and quotation of the Series 003 Notes on the SGX-ST. Such permission will be granted when the Series 003 Notes have been admitted to the Official List of the SGX-ST. The SGX-ST assumes no responsibility for the correctness of any of the statements made, opinions expressed or reports contained herein. Approval in-principle from, admission to the Official List of, and the listing and quotation of the Series 003 Notes on, the SGX-ST are not to be taken as an indication of the merits of the Issuer, its subsidiaries, its associated companies (if any), the Programme or the Series 003 Notes.

By Order of the Board

Wilson Sam
Executive Director and Group Chief Financial Officer
24 May 2023